Tau oligomers are emerging as a key contributor to the synaptic dysfunction that drives cognitive decline associated with the clinical manifestation and progression of Alzheimer’s disease (AD). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.